Category - Developments

Titan Pharmaceuticals’ (NASDAQ:TTNP) development and commercialization partner for Probuphine, closely held Braeburn Pharmaceuticals, announced that the Centers for Medicare & Medicaid Services (CMS) has granted a...

Microbix Biosystems (TSX:MBX) has signed a distribution agreement with Meridian Life Science, a wholly owned unit of Meridian Bioscience (NASDAQ:VIVO), a fully integrated global diagnostic and life sciences company...

Vital Therapies (NASDAQ:VTL) updated its Phase 3 trial, VTL-308, designed to evaluate the ELAD System in subjects with severe acute alcoholic hepatitis. A total of 38 subjects have been enrolled at sites in the U.S. and...

Data from a new study published recently in Urologic Oncology involving men with localized high-risk prostate cancer suggests that the use of 3D Signatures’ (OTCQB:TDSGF; TSX-V:DXD) technology platform, TeloView, may be...

Feltl’s Top Ideas list for 2017 includes Cardiovascular Systems (NASDAQ:CSII) and Kindred Biosciences (NASDAQ:KIN). Analyst Ben Haynor writes that Cardiovascular has strong reimbursement in both below-the-knee and...

Closely held Braeburn Pharmaceuticals filed with U.S. regulators to raise up to $150-million in an initial public offering, seven months after its Probuphine implant to treat opioid addiction was approved by the FDA...

Dipexium Pharmaceuticals (NASDAQ:DPRX) and closely held PLx Pharma have agreed to merge in an all-stock transaction.  Following closing, Dipexium will be renamed PLx Pharma and will operate under the leadership of...

Sales for Microbix Biosystems (TSX:MBX) in the fourth quarter of fiscal 2016 climbed 64% to $3.5-million, representing the highest quarterly revenue ever achieved by the company, from $2.1-million a year earlier. Net...

The Motley Fool investment newsletter selected Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine implant as one of the 12 greatest medical breakthroughs of 2016. In May, the FDA approved the one-of-a-kind buprenorphine...

Arbutus Biopharma (NASDAQ:ABUS) and Spring Bank Pharmaceuticals (NASDAQ:SBPH) agreed to perform collaborative preclinical studies in chronic Hepatitis B virus (HBV). The accord involves the co-administration of Spring...